Company
Novo Nordisk
Official Name: Novo Nordisk A/S
Headquarters: Bagsvaerd, Denmark
Founded: December 21, 1923
Employees: 47,792
CEO: Mr. Lars Fruergaard Jorgensen
Market Cap
kr.2.251 Trillion
DKK as of July 1, 2023
US$329.83 Billion
Novo Nordisk Categories
Denmark
languages
Healthcare
languages
Biotechnology
Denmark Healthcare
Denmark Biotechnology
Company Description
Novo Nordisk is a global healthcare company involved in the research, development, manufacture, and marketing of pharmaceutical products. It operates through two segments: Diabetes and Obesity care, providing products for insulins, GLP-1, oral antidiabetic products, obesity, and other chronic diseases; and Biopharm, offering products for haemophilia, growth disorders, and hormone replacement therapy.
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
Vertex Pharmaceuticals Incorporated
|
$88.79 B |
CSL Limited
|
$85.00 B |
| Marinomed Biotech AG | $84.73 B |
|
Regeneron Pharmaceuticals, Inc.
|
$78.88 B |
|
Moderna, Inc.
|
$46.56 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
|
UnitedHealth Group
|
$428.70 B |
|
Lilly
|
$417.05 B |
|
Johnson & Johnson
|
$412.24 B |
|
Merck
|
$275.82 B |
Roche
|
$241.08 B |
Detailed Description
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Unlock the Power of Financial AI:
Try Disfold AI Free for 7 Days!
Stocks & Indices
Novo Nordisk A/S has the following listings and related stock indices.
Stock: OMXC: NOVO.B wb_incandescent
Stock: FSX: NOVC wb_incandescent
Stock: XETR: NOVC wb_incandescent
Stock: XETR: NOVA wb_incandescent
Stock: FSX: NOVA wb_incandescent
Stock: BMV: NVON wb_incandescent
Stock: NYSE: NVO wb_incandescent
Stock: Bovespa: N1VO34 wb_incandescent
Product & Services
Ozempic, Ryzodeg, Victoza, NovoEight, Activella, Novolin, Levemir, NovoSeven, Norditropin, Tresiba, Xultophy, NovoRapid, Fiasp, Saxenda
Key People
Helge Lund (Chairman) Lars Fruergaard Jørgensen (President & CEO)
Financials
Revenue: DKK 140.80 billion (2021)
Operating income: DKK 52.483 billion (2019)
Net income: DKK 38.951 billion (2019)
Total assets: DKK 125.612 billion (2019)
Total equity: DKK 57.593 billion (2019)